The global interferon beta 1B drugs market is anticipated to grow at a considerable CAGR of 3.1% during the forecast period (2022-2028). Interference beta 1B is the recombinant human interferon drug used for the treatment of multiple sclerosis by slowing the progression of relapsing multiple sclerosis. This drug does not cure multiple sclerosis, however, reduces […]
